Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sanjaya Hebbar

Internal Medicine Oro Valley, AZ Medical Doctor

NPI 1366435455 CMS profile 288791

10370 N La Canada Dr Ste 150, Oro Valley, AZ 85737

Open in the dashboard

General payments

$11,668

715 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sanjaya Hebbar of Oro Valley, AZ is reported in the CMS Open Payments database as having received $11,668 across 715 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,714 150
2024 General $2,865 147
2023 General $2,313 125
2022 General $1,500 87
2021 General $1,130 71
2020 General $268 19
2019 General $877 116

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sanjaya Hebbar
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sanjaya Hebbar were reported at $2,714. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sanjaya Hebbar Internal Medicine median Middle half National median
2019 $877 $159 $48–$570 $163
2020 $268 $119 $33–$402 $114
2021 $1,130 $135 $37–$521 $132
2022 $1,500 $141 $42–$496 $149
2023 $2,313 $149 $45–$519 $160
2024 $2,865 $154 $47–$537 $164
2025 $2,714 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,758 94 payments
  2. GlaxoSmithKline, LLC. $1,114 71 payments
  3. Amgen Inc. $1,037 60 payments
  4. AstraZeneca Pharmaceuticals LP $750 28 payments
  5. Janssen Pharmaceuticals, Inc $531 55 payments
  6. Novartis Pharmaceuticals Corporation $526 63 payments
  7. Lilly USA, LLC $512 35 payments
  8. Novo Nordisk Inc $488 26 payments
  9. Abbott Laboratories $435 17 payments
  10. Pfizer Inc. $435 29 payments
  11. Other $4,082 237 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,662 714 payments
  2. Education $5 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $865 50 payments
  2. UBRELVY $623 32 payments
  3. Repatha $582 29 payments
  4. QULIPTA $569 31 payments
  5. Otezla $558 37 payments
  6. XARELTO $503 53 payments
  7. AIRSUPRA $463 13 payments
  8. AREXVY $457 27 payments
  9. FARXIGA $434 8 payments
  10. VRAYLAR $431 26 payments
  11. Other $9,983 627 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 158 drugs

Part D claims

11,446

Median for Internal Medicine: 777

Drug cost

$1,168,977

Median for Internal Medicine: $73,373

Branded share of claims

17.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 111 $160,354
Eliquis Apixaban Brand 104 $139,324
Xarelto Rivaroxaban Brand 106 $135,121
Humira Pen Adalimumab Brand 13 $88,018
Ozempic Semaglutide Brand 49 $73,695
Rybelsus Semaglutide Brand 28 $71,497
Trulicity Dulaglutide Brand 48 $65,848
Mounjaro Tirzepatide Brand 46 $57,774
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 71 $56,618
Farxiga Dapagliflozin Propanediol Brand 34 $45,370

The 10 drugs with the highest cost, of 158 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$125,182

Of which drugs: $1,843

Medicare patients

600

Average age 75

Services billed

2,204

273 women, 327 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 40%
Diabetes 21%
Ischemic heart disease 21%
Atrial fibrillation 17%
Chronic kidney disease 17%
Heart failure 14%
Depression 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 44 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $209
$209 71 —
CREON
  • AbbVie, Inc. $182
$182 — —
AREXVY
  • GlaxoSmithKline, LLC. $166
$166 — —
MOUNJARO
  • Lilly USA, LLC $155
$155 46 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $140
$140 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 44 with Patron

Records

715 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record